CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced its agenda for the 26th Symposium for Intensive Medicine + Intensive Care in Bremen, Germany from February 24-26, 2016.
In addition, data from the first completed investigator initiated CytoSorb® sepsis study will be presented by Dr. Sigrun Friesecke from Greifswald University, Germany, in a highly anticipated talk entitled, "CytoSorb in Patients with Refractory Septic Shock". Dr. Friesecke and her team are amongst the early pioneers of CytoSorb® usage worldwide, and have utilized it with growing success in patients with varying stages of severe sepsis and septic shock, as well as in liver dysfunction.
Source & Image Credit : Cytosorbents